Today: 19 April 2026
Unilever stock price rises in London despite Trump tariff jitters — what to watch before earnings
19 January 2026
1 min read

Unilever stock price rises in London despite Trump tariff jitters — what to watch before earnings

London, Jan 19, 2026, 08:47 GMT — Regular session

  • Unilever shares climbed roughly 0.7% in early London trading, defying the wider European selloff
  • Markets jolted as U.S. President Donald Trump threatened to impose new tariffs linked to Greenland
  • Investors are eyeing Unilever’s Feb. 12 earnings for clues on its growth and margin outlook

Unilever (ULVR.L) shares climbed roughly 0.7% to 4,793 pence in early London trade Monday, showing resilience amid risk-off headlines sweeping Europe. The stock has slipped about 1.4% year to date.

The pan-European STOXX 600 slid 1.3%, while London’s FTSE 100 dipped 0.4% following U.S. President Donald Trump’s threat to impose more tariffs if the U.S. isn’t allowed to buy Greenland. Trump announced a 10% tariff starting Feb. 1 on goods from several European countries, set to jump to 25% on June 1 if no agreement is reached. U.S. markets were closed Monday for Martin Luther King Jr. Day. ING economists noted, “The rationale for higher tariffs is now even more political and less economic.” Reuters

Timing is crucial for Unilever investors. Consumer staples—firms selling everyday essentials—often attract buyers during bouts of market jitters. Yet, that same churn can rattle currency markets and shake up pricing expectations for global companies.

Unilever is a global consumer goods company with a diverse portfolio covering personal care, home care, and foods. Its personal care lineup includes brands like Dove and TRESemme, while in home care, it owns names such as Cif and Domestos.

Unilever’s next major event is the release of its full-year results. The company plans to report fourth-quarter and full-year 2025 figures on Feb. 12. CEO Fernando Fernandez is also scheduled to present at the Consumer Analyst Group of New York (CAGNY) conference on Feb. 17.

Before releasing its results, Unilever directed investors to a “pre-close aide-mémoire”—a summary of already disclosed or public information—and stressed it offers no new trading update or guidance. The company is gathering analyst consensus to share at a later date. Unilever

Traders are watching closely for signs of how much of last year’s price gains have endured, if volumes are picking up, and what Unilever reveals about input costs and promotions in its main markets.

There’s a risk angle here, too. Safe-haven flows surged after the tariff threat, with analysts cautioning that uncertainty may linger even if the details shift. Vishnu Varathan, head of macro research at Mizuho, said it “throws the so-called agreements out of the window.” Charu Chanana, chief investment strategist at Saxo, warned that “uncertainty can make companies delay capex and supply-chain decisions” — capex being capital spending. Reuters

Unilever is navigating a significant shakeup. After spinning off its Magnum ice cream unit in December, the company completed an 8-for-9 share consolidation, Reuters reported.

The calendar lays it out plainly, though the tape less so: all eyes on Trump’s Feb. 1 tariff deadline for signs of follow-through. Then comes Unilever’s Feb. 12 earnings report, offering a fresh snapshot of sales growth and margins.

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Diageo share price slips after $22bn spirits glut report — here’s what traders watch next
Previous Story

Diageo share price slips after $22bn spirits glut report — here’s what traders watch next

Severn Trent share price rises as UK water outages drag regulators back into focus
Next Story

Severn Trent share price rises as UK water outages drag regulators back into focus

Go toTop